E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Cipla continues to expand its generic portfolio in the US with the launch of pomalidomide capsules for the treatment of adult patients with multiple myeloma.
imphoenix82
Following confirmation of the PDUFA target action date of April 30, 2027, Kowa anticipates a US commercial launch of the K-911 glaucoma eye drop in the second half of 2027, subject to FDA approval.
imphoenix82
If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients with dMMR/MSI-H locally advanced rectal cancer, said GSK.
imphoenix82
Abbott’s Libre Duo 10 Day provides real-time glucose readings for daily diabetes management while continuously monitoring ketone levels in the background.
imphoenix82
Developed by Lakefront in collaboration with Gilead Sciences, gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the US FDA for the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia.
imphoenix82
Amygdala Neurosciences is initially developing ANS-858 as a potential treatment for alcohol use disorder and other substance use disorders.
imphoenix82
With the unit classified as VAI, Aurobindo Pharma said pending applications for multiple inhalers and other dosage forms filed from the facility can now progress through the USFDA’s review process.
imphoenix82
Lilly is calling on regulators, customs agencies, law enforcement authorities, online platforms, and payment companies to shut down the illegal retatrutide black market.
imphoenix82
Aurobindo Pharma said the warning letter to Unit I of Eugia Pharma Specialities will have no impact on existing supplies to the US market.
imphoenix82
Fresenius Kabi is notifying distributors and customers directly about the recall and is arranging for the return of affected products.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
